Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
9 "Gyu Sang Yoo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis
Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2024;56(3):809-824.   Published online December 14, 2023
DOI: https://doi.org/10.4143/crt.2023.920
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is increasing interest in the efficacy of stereotactic ablative radiotherapy (SABR) for treating colorectal cancer (CRC) patients with oligometastases (OM), recently. The purpose of this meta-analysis was to evaluate local control (LC), progression-free survival (PFS), and overall survival (OS) of CRC patients with pulmonary OM treated with SABR and toxicities.
Materials and Methods
Studies that reported SABR for CRC patients with pulmonary OM were searched from MEDLINE and Embase. Treatment outcomes including LC, PFS, OS, and toxicities of grade 3 or higher were assessed.
Results
A total of 19 studies with 1,668 patients were chosen for this meta-analysis. Pooled 1-, 2-, and 3-year LC rates were 83.1%, 69.3%, and 63.9%, respectively. PFS rates were 44.8%, 26.5%, and 21.5% at 1, 2, and 3 years, respectively. OS rates at 1-, 2-, and 3-year were 87.5%, 69.9%, and 60.5%, respectively. The toxicity rate of grade 3 or higher was 3.6%. The effect of dose escalation was meta-analyzed using available studies.
Conclusion
Application of SABR to CRC patients with pulmonary OM achieved modest local control with acceptable toxicity according to the present meta-analysis. Further studies establishing the clinical efficacy of SABR are guaranteed.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • 3,640 View
  • 162 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group’s Comparative Survey Study
Won Kyung Cho, Gyu Sang Yoo, Chai Hong Rim, Jae-Uk Jeong, Eui Kyu Chie, Yong Chan Ahn, Hyeon-Min Cho, Jun Won Um, Yang-Gun Suh, Ah Ram Chang, Jong Hoon Lee, On behalf of the Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2023;55(4):1281-1290.   Published online June 7, 2023
DOI: https://doi.org/10.4143/crt.2023.479
AbstractAbstract PDFPubReaderePub
Purpose
Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary.
Materials and Methods
A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties.
Results
The radiation oncologists chose “bone” more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored “peritoneal seeding” (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that “irrelevant, if all metastatic lesions are amendable to local therapy”, while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed.
Conclusion
This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.

Citations

Citations to this article as recorded by  
  • Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
    Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(4): 1063.     CrossRef
  • 3,129 View
  • 179 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Review Article
Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Cancer Association Oligometastasis Working Group
Cancer Res Treat. 2023;55(3):707-719.   Published online March 15, 2023
DOI: https://doi.org/10.4143/crt.2022.1599
AbstractAbstract PDFPubReaderePub
Introduction of the concept for oligometastasis led to wide application of metastasis-directed local ablative therapies for metastatic colorectal cancer (CRC). By application of the metastasis-directed local ablative therapies including surgical resection, radiofrequency ablation (RFA), and stereotactic ablative body radiotherapy (SABR), the survival outcomes of patients with metastatic CRC have improved. The liver is the most common distant metastatic site in CRC patients, and recently various metastasis-directed local therapies for hepatic oligometastasis from CRC (HOCRC) are widely used. Surgical resection is the first line of metastatic-directed local therapy for HOCRC, but its eligibility is very limited. Alternatively, RFA can be applied to patients who are ineligible for surgical resection of liver metastasis. However, there are some limitations such as inferior local control (LC) compared with surgical resection and technical feasibility based on location, size, and visibility on ultrasonography of the liver metastasis. Recent advances in radiation therapy technology have led to an increase in the use of SABR for liver tumors. SABR is considered complementary to RFA for patients with HOCRC who are ineligible for RFA. Furthermore, SABR can potentially result in better LC for liver metastases > 2-3 cm compared with RFA. In this article, the previous studies regarding curative metastasis-directed local therapies for HOCRC based on the radiation oncologist’s and surgeon’s perspective are reviewed and discussed. In addition, future perspectives regarding SABR in the treatment of HOCRC are suggested.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
    Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
    Radiation Oncology Journal.2024; 42(4): 247.     CrossRef
  • 5,548 View
  • 298 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Original Article
Pediatric cancer
Chronological Analysis of Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Gyu Sang Yoo, Jeong Il Yu, Sungkoo Cho, Youngyih Han, Yoonjin Oh, Do Hoon Lim, Hee Rim Nam, Ji-Won Lee, Ki-Woong Sung, Hyung Jin Shin
Cancer Res Treat. 2022;54(3):907-916.   Published online October 15, 2021
DOI: https://doi.org/10.4143/crt.2021.332
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the early hematological dynamics and acute toxicities between proton beam craniospinal irradiation (PrCSI) and photon beam craniospinal irradiation (PhCSI) for pediatric brain tumors.
Materials and Methods
We retrospectively reviewed patients with pediatric brain tumors who received craniospinal irradiation (CSI). The average change in hemoglobin levels (ΔHbavg), absolute lymphocyte counts (ΔALCavg), and platelet counts (ΔPLTavg) from baseline values was evaluated and compared between the PrCSI and PhCSI groups at 1 and 2 weeks after the initiation of CSI, 1 week before and at the end of radiotherapy, and 3-4 weeks after the completion of radiotherapy using t test and mixed-model analysis.
Results
The PrCSI and PhCSI groups consisted of 36 and 30 patients, respectively. There were no significant differences in ΔHbavg between the two groups at any timepoint. However, ΔALCavg and ΔPLTavg were significantly lower in the PhCSI group than in PrCSI group at every timepoint, demonstrating that PrCSI resulted in a significantly lower rate of decline and better recovery of absolute lymphocyte and platelet counts. The rate of grade 3 acute anemia was significantly lower in the PrCSI group than in in the PhCSI group.
Conclusion
PrCSI showed a lower rate of decline and better recovery of absolute lymphocyte and platelet counts than PhCSI in the CSI for pediatric brain tumors. Grade 3 acute anemia was significantly less frequent in the PrCSI group than in the PhCSI group. Further large-scale studies are warranted to confirm these results.

Citations

Citations to this article as recorded by  
  • Pediatric CNS Radiation Oncology: Recent Developments and Novel Techniques
    Justin Oh, Samir Patel, Mary-Pat Schlosser, Andrew J. Arifin, Carol Oliveira, Anne-Marie Charpentier, Derek S. Tsang
    Current Oncology.2025; 32(3): 180.     CrossRef
  • Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study
    Linn Söderlund Diaz, Måns Agrup, Anna Askild, Anna Embring, Jacob Engellau, Ingrid Fagerström Kristensen, Anna Flejmer, Charlotta Fröjd, Martin P Nilsson, Anna Maja Svärd, Angelica Walfridsson, Malin Blomstrand
    Journal of Neuro-Oncology.2025;[Epub]     CrossRef
  • Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma
    Kyungmi Yang, Joong Hyun Ahn, Sook-Young Woo, Sang Hoon Jung, Ki Woong Sung, Ji Won Lee, Do Hoon Lim
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Comparison of Craniospinal Irradiation Using Proton Beams According to Irradiation Method and Initial Experience Treating Pediatric Patients
    Nobuyoshi Fukumitsu, Hikaru Kubota, Masayuki Mima, Yusuke Demizu, Takeshi Suzuki, Daiichiro Hasegawa, Yoshiyuki Kosaka, Atsufumi Kawamura, Toshinori Soejima
    Advances in Radiation Oncology.2023; 8(5): 101251.     CrossRef
  • Proton versus photon radiation therapy: A clinical review
    Zhe Chen, Michael M. Dominello, Michael C. Joiner, Jay W. Burmeister
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Shifting Strategies in the Treatment of Pediatric Craniopharyngioma
    Segev Gabay, Thomas E. Merchant, Frederick A. Boop, Jonathan Roth, Shlomi Constantini
    Current Oncology Reports.2023; 25(12): 1497.     CrossRef
  • 6,292 View
  • 141 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Special Article
Physical and Biological Characteristics of Particle Therapy for Oncologists
Hwa Kyung Byun, Min Cheol Han, Kyungmi Yang, Jin Sung Kim, Gyu Sang Yoo, Woong Sub Koom, Yong Bae Kim
Cancer Res Treat. 2021;53(3):611-620.   Published online June 16, 2021
DOI: https://doi.org/10.4143/crt.2021.066
AbstractAbstract PDFPubReaderePub
Particle therapy is a promising and evolving modality of radiotherapy that can be used to treat tumors that are radioresistant to conventional photon beam radiotherapy. It has unique biological and physical advantages compared with conventional radiotherapy. The characteristic feature of particle therapy is the “Bragg peak,” a steep and localized peak of dose, that enables precise delivery of the radiation dose to the tumor while effectively sparing normal organs. Especially, the charged particles (e.g., proton, helium, carbon) cause a high rate of energy loss along the track, thereby leading to high biological effectiveness, which makes particle therapy attractive. Using this property, the particle beam induces more severe DNA double-strand breaks than the photon beam, which is less influenced by the oxygen level. This review describes the general biological and physical aspects of particle therapy for oncologists, including non-radiation oncologists and beginners in the field.

Citations

Citations to this article as recorded by  
  • Tuning the range-energy relationship parameter for Monte Carlo-based proton Bragg curve spreading in muscle, bone, and polymethylmethacrylate
    Behzad Aminafshar, Hamid Reza Baghani, Ali Asghar Mowlavi
    Radiological Physics and Technology.2025; 18(1): 300.     CrossRef
  • Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy
    Lijuan Zhang, Zhihong Zhang, Yiqiao Wang, Yu Zhu, Ziying Wang, Hongwei Wan
    Radiotherapy and Oncology.2025; 204: 110712.     CrossRef
  • Physiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons
    Filippo Torrisi, Francesco Paolo Cammarata, Valentina Bravatà, Marco Calvaruso, Cristiana Alberghina, Anna Maria Pavone, Giada Petringa, Giuseppe Antonio Pablo Cirrone, Simona Denaro, Anna Gervasi, Simona D’Aprile, Nunzio Vicario, Emanuele Scifoni, Pietro
    Scientific Reports.2025;[Epub]     CrossRef
  • Effect of FLASH proton therapy on primary bronchial epithelial cell organoids
    Merian E. Kuipers, Floriane van Liefferinge, Ernst van der Wal, Marta Rovituso, Annelies M. Slats, Pieter S. Hiemstra, Krista C.J. Van Doorn-Wink
    Clinical and Translational Radiation Oncology.2025; 52: 100927.     CrossRef
  • Exploring biochemical considerations for diffusive alpha radiation therapy (DaRT) models
    Peter Dukakis, Jesús J. Bosque, Alejandro Bertolet
    Physica Medica.2025; 131: 104947.     CrossRef
  • STAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis
    Yanliang Chen, Dandan Wang, Hongtao Luo, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Qiuning Zhang, Wenzhen Yuan
    Molecular and Cellular Biochemistry.2025;[Epub]     CrossRef
  • Uncertainty evaluation in simulation study on range-shift estimation due to statistical noise in secondary electron bremsstrahlung from a small number of carbon ions
    Michiko Tsuda, Mitsutaka Yamaguchi, Takuya Yabe, Yuto Nagao, Naoki Kawachi, Makoto Sakai, Tomihiro Kamiya, Wataru Kada, Hiroshi Watabe
    Japanese Journal of Applied Physics.2025; 64(4): 047001.     CrossRef
  • Monte Carlo simulation of beam quality correction factor kQ for carbon-ion beams using FLUKA and GATE for selected cylindrical and plane-parallel ionization chambers
    Jessica Stolzenberg, Pascal Saße, Yuri Simeonov, Björn Poppe, Kilian-Simon Baumann, Hui Khee Looe
    Physics in Medicine & Biology.2025; 70(8): 085017.     CrossRef
  • Effects of Combined Neutron and Proton Beam Radiation Exposure on the Pool of Breast Cancer Stem Cells In Vitro
    I. A. Zamulaeva, O. N. Matchuk, K. A. Churyukina, V. O. Saburov, S. N. Koryakin, S. A. Ivanov, A. D. Kaprin, E. A. Krasavin
    Physics of Particles and Nuclei Letters.2025; 22(1): 77.     CrossRef
  • Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report
    Ming-Wei Ma, Zi-Shen Wang, Hong-Zhen Li, Xian-Shu Gao, Chao Liu, Xue-Ying Ren, Wei-Li Zhang, Kai-Wei Yang
    Medical Dosimetry.2024; 49(1): 41.     CrossRef
  • Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma
    Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
    Radiotherapy and Oncology.2024; 190: 109971.     CrossRef
  • The rationale for a carbon ion radiation therapy facility in Australia
    David I. Thwaites, Dale A. Prokopovich, Richard F. Garrett, Annette Haworth, Anatoly Rosenfeld, Verity Ahern
    Journal of Medical Radiation Sciences.2024; 71(S2): 59.     CrossRef
  • Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma
    Fereshteh Koosha, Mahdieh Ahmadikamalabadi, Mohadesseh Mohammadi
    Advances in Radiation Oncology.2024; 9(5): 101465.     CrossRef
  • Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro
    Bahar Cepni, Thomas Tessonnier, Ivana Dokic, Stephan Brons, Bouchra Tawk, Andrea Mairani, Amir Abdollahi, Jürgen Debus, Klaus Herfarth, Jakob Liermann
    Cancers.2024; 16(8): 1497.     CrossRef
  • A review and bibliometric analysis of global research on proton radiotherapy
    Ge Song, Zhi Zheng, Yingming Zhu, Yaoting Wang, Song Xue
    Medicine.2024; 103(19): e38089.     CrossRef
  • Assessing the Impact of Charged Particle Radiation Therapy for Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis
    Mingyu Tan, Yanliang Chen, Tianqi Du, Qian Wang, Xun Wu, Qiuning Zhang, Hongtao Luo, Zhiqiang Liu, Shilong Sun, Kehu Yang, Jinhui Tian, Xiaohu Wang
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors
    Fabiana Gregucci, Kathryn Beal, Jonathan P. S. Knisely, Paul Pagnini, Alba Fiorentino, Elisabetta Bonzano, Claire I. Vanpouille-Box, Babacar Cisse, Susan C. Pannullo, Philip E. Stieg, Silvia C. Formenti
    Cancers.2024; 16(11): 2047.     CrossRef
  • Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling
    Jörg Hänze, Lilly M. Mengen, Marco Mernberger, Dinesh Kumar Tiwari, Thomas Plagge, Andrea Nist, Florentine S. B. Subtil, Ulrike Theiss, Fabian Eberle, Katrin Roth, Matthias Lauth, Rainer Hofmann, Rita Engenhart-Cabillic, Thorsten Stiewe, Axel Hegele
    Radiation Oncology.2024;[Epub]     CrossRef
  • Dose-averaged linear energy transfer within the gross tumor volume of non-small-cell lung cancer affects the local control in carbon-ion radiotherapy
    Guangsheng Li, Ningyi Ma, Weiwei Wang, Jian Chen, Jingfang Mao, Guoliang Jiang, Kailiang Wu
    Radiotherapy and Oncology.2024; 201: 110584.     CrossRef
  • Clinical indications and future directions of carbon-ion radiotherapy: a narrative review
    Seo Hee Choi, Woong Sub Koom, Hong In Yoon, Kyung Hwan Kim, Chan Woo Wee, Jaeho Cho, Yong Bae Kim, Ki Chang Keum, Ik Jae Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Circadian rhythms and cancer: implications for timing in therapy
    Mohamed El-Tanani, Syed Arman Rabbani, Areeg Anwer Ali, Ibrahim Ghaleb Ali Alfaouri, Hamdi Al Nsairat, Israa Hamid Al-Ani, Alaa A. Aljabali, Manfredi Rizzo, Dimitrios Patoulias, Mohammad Ahmed Khan, Suhel Parvez, Yahia El-Tanani
    Discover Oncology.2024;[Epub]     CrossRef
  • The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
    Min Cheol Han, Seo Hee Choi, Chae-Seon Hong, Yong Bae Kim, Woong Sub Koom, Jin Sung Kim, Jaeho Cho, Chan Woo Wee, Changhwan Kim, Jong Won Park, Soorim Han, Heejeong Lee, Hong In Yoon, Ik Jae Lee, Ki Chang Keum
    Radiation Oncology Journal.2024; 42(4): 295.     CrossRef
  • Preservation of Neurocognition after Proton Beam Radiation Therapy for Intracranial Tumors: First Results from REGI-MA-002015
    Birgit Flechl, Lisa Konrath, Carola Lütgendorf-Caucig, Milana Achtaewa, Eugen B. Hug, Petra Georg
    International Journal of Radiation Oncology*Biology*Physics.2023; 115(5): 1102.     CrossRef
  • Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity
    Farzad Taghizadeh-Hesary, Mohammad Houshyari, Mohammad Farhadi
    Journal of Cancer Research and Clinical Oncology.2023; 149(9): 6719.     CrossRef
  • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player
    Maria Manuela Rosado, Claudio Pioli
    Cancers.2023; 15(4): 1093.     CrossRef
  • Particle radiotherapy for breast cancer
    Hanguang Ruan, Masahiko Okamoto, Tatsuya Ohno, Yang Li, Yuan Zhou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer
    Han-Back Shin, Changhwan Kim, Min Cheol Han, Chae-Seon Hong, Seyjoon Park, Woong Sub Koom, Jin Sung Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Particle Reirradiation of Malignant Epithelial and Neuroectodermal Sinonasal Tumors: A Case Series from CNAO
    Barbara Vischioni, Rossana Ingargiola, Maria Bonora, Sara Ronchi, Anna Maria Camarda, Stefania Russo, Eleonora Rossi, Giuseppe Magro, Alfredo Mirandola, Ester Orlandi
    Journal of Clinical Medicine.2023; 12(7): 2624.     CrossRef
  • Gold-Nanoparticles-Enhanced Production of Reactive Oxygen Species in Cells at Spread-Out Bragg Peak under Proton Beam Radiation
    Chang-Yun Lo, Shiao-Wen Tsai, Huan Niu, Fang-Hsin Chen, Hsiao-Chien Hwang, Tsi-Chian Chao, Ing-Tsung Hsiao, Jiunn-Woei Liaw
    ACS Omega.2023; 8(20): 17922.     CrossRef
  • Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis
    Yanliang Chen, Hongtao Luo, Ruifeng Liu, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Zhiqiang Liu, Shilong Sun, Qiuning Zhang, Xiaohu Wang
    Radiation Oncology.2023;[Epub]     CrossRef
  • Particle radiotherapy in the era of radioimmunotherapy
    Zihan Zhou, Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu
    Cancer Letters.2023; 567: 216268.     CrossRef
  • A narrative review of particle therapy in cancer
    Mayakannan Krishnan, C. P. Ranjith
    Cancer Research, Statistics, and Treatment.2023; 6(2): 248.     CrossRef
  • Proton Beam Therapy in the Reirradiation Setting of Brain and Base of Skull Tumour Recurrences
    S. Gaito, N.G. Burnet, M.C. Aznar, G. Marvaso, B.A. Jereczek-Fossa, A. Crellin, D. Indelicato, S. Pan, R. Colaco, R. Rieu, E. Smith, G. Whitfield
    Clinical Oncology.2023; 35(10): 673.     CrossRef
  • Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
    Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
    Clinical and Molecular Hepatology.2023; 29(4): 945.     CrossRef
  • Proton Compared to X-Irradiation Induces Different Protein Profiles in Oral Cancer Cells and Their Derived Extracellular Vesicles
    Inga Solgård Juvkam, Olga Zlygosteva, Mateusz Sitarz, Bernd Thiede, Brita Singers Sørensen, Eirik Malinen, Nina Jeppesen Edin, Tine Merete Søland, Hilde Kanli Galtung
    International Journal of Molecular Sciences.2023; 24(23): 16983.     CrossRef
  • DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks
    Veronika Mladenova, Emil Mladenov, Martin Stuschke, George Iliakis
    Molecules.2022; 27(5): 1540.     CrossRef
  • Editorial: Medical Application and Radiobiology Research of Particle Radiation
    Fei Ye, Chao Sun, Yi Xie, Bing Wang, Lu Cai
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer?
    Eui Kyu Chie, Yong Chan Ahn
    Cancer Research and Treatment.2021; 53(3): 609.     CrossRef
  • 10,976 View
  • 451 Download
  • 46 Web of Science
  • 38 Crossref
Close layer
Original Articles
General
Patterns of Proton Beam Therapy Use in Clinical Practice between 2007 and 2019 in Korea
Sung Uk Lee, Kyungmi Yang, Sung Ho Moon, Yang-Gun Suh, Gyu Sang Yoo
Cancer Res Treat. 2021;53(4):935-943.   Published online May 17, 2021
DOI: https://doi.org/10.4143/crt.2021.409
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Proton beam therapy (PBT) is a state-of-the-art technology employed in radiotherapy (RT) for cancer patients. This study characterized how PBT has been used in clinical practice in Korea.
Materials and Methods
Patients who received any type of RT between 2007 and 2019 were identified from the radiation oncology registry of the two PBT facilities operating in Korea (National Cancer Center and Samsung Medical Center). The chi-square test was used to identify patient- and treatment-related characteristics associated with the receipt of PBT.
Results
A total of 54,035 patients had been treated with some form of RT in the two institutions, of whom 5,398 received PBT (10.0%). The number of patients who receive PBT has gradually increased since PBT first started, from 162 patients in 2007 to 1,304 patients in 2019. Among all types of cancer, PBT use in liver cancer has been steadily increasing from 20% in 2008-2009 to 32% in 2018-2019. In contrast, that in prostate cancer has been continuously decreasing from 20% in 2008-2009 to < 10% in 2018-2019. Male sex, very young or old age, stage I-II disease, residency in non-capital areas, a definitive setting, a curative treatment aim, enrollment in a clinical trial, re-irradiation and insurance coverage were significantly associated with the receipt of PBT (all p < 0.05).
Conclusion
Since PBT started in Korea, the number of patients receiving PBT has increased to more than 1,000 per year and treatment indications have expanded. Liver cancer is the most common primary tumor among all PBT cases in Korea.

Citations

Citations to this article as recorded by  
  • “Particle therapy - future for the Baltic states?” – synthesis of the expert workshop report
    Kristaps Paļskis, Erika Korobeinikova, Dace Bogorada-Saukuma, Anna Maria Camarda, Rebecca Taylor, Elena Benedetto, Edgars Mamis, Maija Radziņa, Andrejs Ērglis, Diana Adliene, Manjit Dosanjh, Maurizio Vretenar, Toms Torims
    Health and Technology.2024; 14(5): 965.     CrossRef
  • Proton Therapy in The Treatment of Head And Neck Cancers- Review
    Kamila Bała, Yana Samovich, Karolina Dorobisz
    Current Oncology Reports.2024; 26(11): 1380.     CrossRef
  • PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer
    J. Isabelle Choi, Camille Hardy-Abeloos, Alicia Lozano, Alexandra Hanlon, Carlos Vargas, John H. Maduro, Julie Bradley, Birgitte Offersen, Bruce Haffty, Mark Pankuch, Richard Amos, Nalee Kim, Shannon M. MacDonald, Youlia Kirova, Robert W. Mutter
    Clinical and Translational Radiation Oncology.2024; 48: 100847.     CrossRef
  • Recent trends in radiotherapy use for major cancers in Korea
    Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh
    Japanese Journal of Clinical Oncology.2023; 53(12): 1177.     CrossRef
  • 7,235 View
  • 215 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Genitourinary cancer
Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma
Gyu Sang Yoo, Won Park, Hongryull Pyo, Byong Chang Jeong, Hwang Gyun Jeon, Minyong Kang, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Byung Kwan Park, Chan Kyo Kim, Sung Yoon Park, Ghee Young Kwon
Cancer Res Treat. 2022;54(1):218-225.   Published online April 15, 2021
DOI: https://doi.org/10.4143/crt.2020.1373
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate the risk factors and patterns of locoregional recurrence (LRR) after radical nephrectomy (RN) in patients with locally advanced renal cell carcinoma (RCC).
Materials and Methods
We retrospectively analyzed 245 patients who underwent RN for non-metastatic pT3-4 RCC from January 2006 to January 2016. We analyzed the risk factors associated with poor locoregional control using Cox regression. Anatomical mapping was performed on reference computed tomography scans showing intact kidneys.
Results
The median follow-up duration was 56 months (range, 1 to 128 months). Tumor extension to renal vessels or the inferior vena cava (IVC) and Fuhrman’s nuclear grade IV were identified as independent risk factors of LRR. The 5-year actuarial LRR rates in groups with no risk factor, one risk factor, and two risk factors were 2.3%, 19.8%, and 30.8%, respectively (p < 0.001). The locations of LRR were distributed as follows: aortocaval area (n=2), paraaortic area (n=4), retrocaval area (n=5), and tumor bed (n=11). No LRR was observed above the celiac axis (CA) or under the inferior mesenteric artery (IMA).
Conclusion
Tumor extension to renal vessels or the IVC and Fuhrman’s nuclear grade IV were the independent risk factors associated with LRR after RN for pT3-4 RCC. The locations of LRR after RN for RCC were distributed in the tumor bed and regional lymphatic area from the bifurcation of the CA to that of the IMA.

Citations

Citations to this article as recorded by  
  • Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
    Andreea Ioana Parosanu, Cornelia Nititpir, Ioana Miruna Stanciu, Catalin Baston
    Biomedicines.2025; 13(3): 543.     CrossRef
  • Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study
    Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se
    Scientific Reports.2024;[Epub]     CrossRef
  • Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
    Dylan M Buller, Maria Antony, Benjamin T Ristau
    OncoTargets and Therapy.2023; Volume 16: 49.     CrossRef
  • 7,095 View
  • 153 Download
  • 5 Web of Science
  • 3 Crossref
Close layer
Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer
Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu, Doo Ho Choi, Won Kyung Cho, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yong Beom Cho, Yoon Ah Park, Kyoung Doo Song, Seok-Hyung Kim, Sang Yun Ha
Cancer Res Treat. 2020;52(2):446-454.   Published online September 25, 2019
DOI: https://doi.org/10.4143/crt.2019.261
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the role of carcinoembryonic antigen (CEA) levels in improving the performance of magnetic resonance imaging (MRI) for the prediction of pathologic response after the neoadjuvant chemoradiation (NCRT) for patients with rectal cancer.
Materials and Methods
We retrospectively reviewed the medical records of 524 rectal cancer patients who underwent NCRT and total mesorectal excision between January 2009 and December 2014. The performances of MRI with or without CEA parameters (initial CEA and CEA dynamics) for prediction of pathologic tumor response grade (pTRG) were compared by receiver-operating characteristic analysis with DeLong’s method. Cox regression was used to identify the independent factors associated to pTRG and disease-free survival (DFS) after NCRT.
Results
The median follow-up was 64.0 months (range, 3.0 to 113.0 months). On multivariate analysis, poor tumor regression grade on MRI (mrTRG; p < 0.001), initial CEA (p < 0.001) and the mesorectal fascia involvement on MRI before NCRT (mrMFI; p=0.054) showed association with poor pTRG. The mrTRG plus CEA parameters showed significantly improved performances in the prediction of pTRG than mrTRG alone. All of mrTRG, mrMFI, and initial CEA were also identified as independent factors associated with DFS. The initial CEA further discriminated DFS in the subgroups with good mrTRG or that without mrMFI.
Conclusion
The CEA parameters significantly improved the performance of MRI in the prediction of pTRG after NCRT for patients with rectal cancer. The DFS was further discriminated by initial CEA level in the groups with favorable MRI parameters.

Citations

Citations to this article as recorded by  
  • Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement
    Jeong Ha Lee, Nalee Kim, Jeong Il Yu, Gyu Sang Yoo, Hee Chul Park, Woo-Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin, Joon Oh Park, Seung Tae Kim, Young Suk Park, Jeeyun Lee, Won Ki Kang
    Radiation Oncology Journal.2024; 42(2): 130.     CrossRef
  • Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade
    S. Qin, Y. Chen, K. Liu, Y. Li, Y. Zhou, W. Zhao, P. Xin, Q. Wang, S. Lu, H. Wang, N. Lang
    Cancer/Radiothérapie.2024; 28(4): 341.     CrossRef
  • Body composition parameters combined with blood biomarkers and magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Jianguo Yang, Qican Deng, Zhenzhou Chen, Yajun Chen, Zhongxue Fu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Xinyu Shi, Min Zhao, Bo Shi, Guoliang Chen, Huihui Yao, Junjie Chen, Daiwei Wan, Wen Gu, Songbing He
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist’s perspective
    Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High-Resolution T2-Weighted MRI to Evaluate Rectal Cancer: Why Variations Matter
    Kirsten L Gormly
    Korean Journal of Radiology.2021; 22(9): 1475.     CrossRef
  • MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology
    Seong Ho Park, Seung Hyun Cho, Sang Hyun Choi, Jong Keon Jang, Min Ju Kim, Seung Ho Kim, Joon Seok Lim, Sung Kyoung Moon, Ji Hoon Park, Nieun Seo
    Korean Journal of Radiology.2020; 21(7): 812.     CrossRef
  • 7,285 View
  • 183 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2019;51(3):1041-1051.   Published online November 1, 2018
DOI: https://doi.org/10.4143/crt.2018.424
AbstractAbstract PDFPubReaderePub
Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.

Citations

Citations to this article as recorded by  
  • Investigation of the clinical benefits of regular breath-holding training utilizing surface guided radiation therapy technology for patients with left breast cancer
    Hongming Li, Zheng Miao, Jie Shen, Jianing Xiao, Zhiwei Yang, Wei Tian, Xiansong Sun, Zhen Zhou, Jing Shen, Jie Qiu
    Journal of Radiation Research and Applied Sciences.2025; 18(2): 101393.     CrossRef
  • 21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery
    Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
    The Breast.2024; 74: 103679.     CrossRef
  • Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping
    Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman
    Radiation.2024; 4(1): 85.     CrossRef
  • Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
    Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
    BJS Open.2024;[Epub]     CrossRef
  • Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery
    Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
    Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee
    Annals of Surgical Oncology.2022; 29(10): 6163.     CrossRef
  • Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
    Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
    BMC Cancer.2022;[Epub]     CrossRef
  • Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
    Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap
    Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso
    Scientific Reports.2019;[Epub]     CrossRef
  • 9,295 View
  • 317 Download
  • 11 Web of Science
  • 9 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP